Dermira

Lilly completes acquisition of Dermira

Lilly completes acquisition of Dermira

INDIANAPOLIS — Eli Lilly and Co. announced the successful completion of its acquisition of Dermira. The acquisition expands Lilly’s immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity that is being evaluated in a Phase 3 clinical development program for the treatment of moderate-to-severe atopic

Dermira gets FDA approval for Qbrexza cloth

Dermira gets FDA approval for Qbrexza cloth

MENLO PARK, Calif. — Dermira announced that the U.S. Food and Drug Administration (FDA) has approved Qbrexza (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Primary axillary hyperhidrosis, also commonly known as excessive underarm sweating, is a chronic medical skin condition